BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 25965974)

  • 1. Functional screening identifies MCT4 as a key regulator of breast cancer cell metabolism and survival.
    Baenke F; Dubuis S; Brault C; Weigelt B; Dankworth B; Griffiths B; Jiang M; Mackay A; Saunders B; Spencer-Dene B; Ros S; Stamp G; Reis-Filho JS; Howell M; Zamboni N; Schulze A
    J Pathol; 2015 Oct; 237(2):152-65. PubMed ID: 25965974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways.
    Yang L; Hou Y; Yuan J; Tang S; Zhang H; Zhu Q; Du YE; Zhou M; Wen S; Xu L; Tang X; Cui X; Liu M
    Oncotarget; 2015 Sep; 6(28):25755-69. PubMed ID: 26342198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monocarboxylate transporter 4, associated with the acidification of synovial fluid, is a novel therapeutic target for inflammatory arthritis.
    Fujii W; Kawahito Y; Nagahara H; Kukida Y; Seno T; Yamamoto A; Kohno M; Oda R; Taniguchi D; Fujiwara H; Ejima A; Kishida T; Mazda O; Ashihara E
    Arthritis Rheumatol; 2015 Nov; 67(11):2888-96. PubMed ID: 26213210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of acid-extruding ion transporters in regulation of breast cancer cell growth in a 3-dimensional microenvironment.
    Andersen AP; Flinck M; Oernbo EK; Pedersen NB; Viuff BM; Pedersen SF
    Mol Cancer; 2016 Jun; 15(1):45. PubMed ID: 27266704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome.
    Doyen J; Trastour C; Ettore F; Peyrottes I; Toussant N; Gal J; Ilc K; Roux D; Parks SK; Ferrero JM; Pouysségur J
    Biochem Biophys Res Commun; 2014 Aug; 451(1):54-61. PubMed ID: 25058459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231.
    Gallagher SM; Castorino JJ; Wang D; Philp NJ
    Cancer Res; 2007 May; 67(9):4182-9. PubMed ID: 17483329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of MCT4 for lactate exchange promotes the cytotoxicity of NK cells in breast carcinoma.
    Long Y; Gao Z; Hu X; Xiang F; Wu Z; Zhang J; Han X; Yin L; Qin J; Lan L; Yin F; Wang Y
    Cancer Med; 2018 Sep; 7(9):4690-4700. PubMed ID: 30051648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4.
    Hong CS; Graham NA; Gu W; Espindola Camacho C; Mah V; Maresh EL; Alavi M; Bagryanova L; Krotee PAL; Gardner BK; Behbahan IS; Horvath S; Chia D; Mellinghoff IK; Hurvitz SA; Dubinett SM; Critchlow SE; Kurdistani SK; Goodglick L; Braas D; Graeber TG; Christofk HR
    Cell Rep; 2016 Feb; 14(7):1590-1601. PubMed ID: 26876179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer.
    Curry JM; Tuluc M; Whitaker-Menezes D; Ames JA; Anantharaman A; Butera A; Leiby B; Cognetti DM; Sotgia F; Lisanti MP; Martinez-Outschoorn UE
    Cell Cycle; 2013 May; 12(9):1371-84. PubMed ID: 23574725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration.
    Gao HJ; Zhao MC; Zhang YJ; Zhou DS; Xu L; Li GB; Chen MS; Liu J
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1151-62. PubMed ID: 25446815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear factor E2-related factor-2 has a differential impact on MCT1 and MCT4 lactate carrier expression in colonic epithelial cells: a condition favoring metabolic symbiosis between colorectal cancer and stromal cells.
    Diehl K; Dinges LA; Helm O; Ammar N; Plundrich D; Arlt A; Röcken C; Sebens S; Schäfer H
    Oncogene; 2018 Jan; 37(1):39-51. PubMed ID: 28846107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies.
    Baek G; Tse YF; Hu Z; Cox D; Buboltz N; McCue P; Yeo CJ; White MA; DeBerardinis RJ; Knudsen ES; Witkiewicz AK
    Cell Rep; 2014 Dec; 9(6):2233-49. PubMed ID: 25497091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis.
    Kim HK; Lee I; Bang H; Kim HC; Lee WY; Yun SH; Lee J; Lee SJ; Park YS; Kim KM; Kang WK
    Mol Cancer Ther; 2018 Apr; 17(4):838-848. PubMed ID: 29483215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monocarboxylate transporters in breast cancer and adipose tissue are novel biomarkers and potential therapeutic targets.
    Li Z; Wu Q; Sun S; Wu J; Li J; Zhang Y; Wang C; Yuan J; Sun S
    Biochem Biophys Res Commun; 2018 Jul; 501(4):962-967. PubMed ID: 29775610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer.
    Todenhöfer T; Seiler R; Stewart C; Moskalev I; Gao J; Ladhar S; Kamjabi A; Al Nakouzi N; Hayashi T; Choi S; Wang Y; Frees S; Daugaard M; Oo HZ; Fisel P; Schwab M; Schaeffeler E; Douglas J; Hennenlotter J; Bedke J; Gibb EA; Fazli L; Stenzl A; Black PC
    Mol Cancer Ther; 2018 Dec; 17(12):2746-2755. PubMed ID: 30262589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis.
    Lee JY; Lee I; Chang WJ; Ahn SM; Lim SH; Kim HS; Yoo KH; Jung KS; Song HN; Cho JH; Kim SY; Kim KM; Lee S; Kim ST; Park SH; Lee J; Park JO; Park YS; Lim HY; Kang WK
    Oncotarget; 2016 Jul; 7(28):43492-43503. PubMed ID: 27224918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers.
    Witkiewicz AK; Whitaker-Menezes D; Dasgupta A; Philp NJ; Lin Z; Gandara R; Sneddon S; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
    Cell Cycle; 2012 Mar; 11(6):1108-17. PubMed ID: 22313602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo pH in metabolic-defective Ras-transformed fibroblast tumors: key role of the monocarboxylate transporter, MCT4, for inducing an alkaline intracellular pH.
    Chiche J; Le Fur Y; Vilmen C; Frassineti F; Daniel L; Halestrap AP; Cozzone PJ; Pouysségur J; Lutz NW
    Int J Cancer; 2012 Apr; 130(7):1511-20. PubMed ID: 21484790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential.
    Knudsen ES; Balaji U; Freinkman E; McCue P; Witkiewicz AK
    Oncotarget; 2016 Nov; 7(48):78396-78411. PubMed ID: 27623078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target.
    Gerlinger M; Santos CR; Spencer-Dene B; Martinez P; Endesfelder D; Burrell RA; Vetter M; Jiang M; Saunders RE; Kelly G; Dykema K; Rioux-Leclercq N; Stamp G; Patard JJ; Larkin J; Howell M; Swanton C
    J Pathol; 2012 Jun; 227(2):146-56. PubMed ID: 22362593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.